Clinical Trial

Quadruple Immunotherapy for Neuroblastoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-02-22; most recent amendment 2025-09-08.
Trial Details
NCT Number NCT05754684
Lead Sponsor Hong Kong Children's Hospital
Collaborators: The University of Hong Kong
Conditions Neuroblastoma Recurrent
Enrollment 29 participants
Start Date 2022-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-15